Citations

Clear

4847 citation(s) found for "Tu, Eric".

Evaluating Physician Concordance in Interpretation of Tracheobronchomalacia Diagnosis and Phenotyping Using Dynamic Expiratory Chest Computed Tomography
Cortes-Puentes, Gustavo A. , Matatko, M., Bartholmai, Brian J. , Edell, Eric S. , Bartholmai, Brian J , Lim, Kaiser G.

Mayo Clinic

No container title available | December 20, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5105444/v1 Get It

Abstract Background: Tracheobronchomalacia (TBM) presents diagnostic challenges due to its nonspecific symptoms and variability in diagnostic methods. This study evaluates physician concordance in TBM diagnosis and phenotyping using chest computed tomography (CT) scans with dynamic expiratory views. Methods: We conducted a retrospective cross-sectional study at Mayo Clinic Rochester, analyzing 150 patients with dynamic expiratory CT scans. Three specialists—a thoracic radiologist, a bronchoscopist, and a pulmonologist—reviewed identical CT scans, blinded to prior interpretations. Inter-rater agreement was assessed using Fleiss's Kappa for TBM diagnosis and Cohen's Kappa for TBM phenotype classification into six categories: No TBM, Excessive Dynamic Airway Collapse (EDAC), Crescent Type, Circumferential Type, Saber-Sheath Type, and Mixed Type. Results: Among the 150 patients, 54 (36%) were diagnosed with TBM or EDAC. TBM was more prevalent in males, older individuals, and smokers. Agreement among specialists was substantial for TBM diagnosis (Fleiss’s Kappa = 0.61, p < 0.001) but moderate for phenotype classification (Fleiss’s Kappa = 0.52, p < 0.001). The highest concordance was between the thoracic radiologist and the pulmonologist (Cohen's Kappa = 0.68), while the lowest was between the bronchoscopist and other specialists. Conclusion: There is substantial agreement in TBM diagnosis using chest CT scans with dynamic expiratory views, but moderate variability in phenotyping. Standardizing criteria and integrating pulmonary function testing could enhance diagnostic consistency and clinical relevance.
County Level Social Determinants of Health and Correlation with Chronic Obstructive Pulmonary Disease Prevalence in the United States
Puentes, G.A. Cortes, DeMartino, Erin S. , Harris, Benjamin R.E., Cortes Puentes, Gustavo A, Harris, B. , Zheutlin, Alexander R. , Stulberg, Eric

Mayo Clinic

Annals of the American Thoracic Society | December 19, 2024 | Volume: 22 | Issue: 4 | Pages: 623-627

10.1513/annalsats.202406-667rl | PMID 39700512 Get It

Trends and disparities in cardiovascular disease–related mortality among adults with myeloproliferative neoplasms in USA
Agarwal, Siddharth , Khan, Muhammad Shahzeb , Al‐Juhaishi, Taha , Naqash, Abdul Rafeh , Guha, Avirup , Barac, Ana , Khan, Muhammad Shahzeb , Al-Juhaishi, Taha , Guha, Avirup , Barac, Ana , Naqash, Abdul Rafeh , Agarwal, Siddharth , Qamar, Usama , Yang, Eric H. , Asad, Zain Ul Abideen

Mayo Clinic

European Heart Journal Open | December 18, 2024 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/ehjopen/oeae101 | PMID 39781540 Get It

Abstract Aims We aimed to perform a retrospective cohort study using the Centers for Disease Control and Prevention’s (CDC’s) Wide-Ranging Online Data for Epidemiologic Research (WONDER) database to analyse the trends in cardiovascular disease (CVD)–related mortality in patients with myeloproliferative neoplasms (MPNs) from 1999 to 2020. Methods and results We analysed the death certificate data from the CDC WONDER database from 1999 to 2020 for CVD with co-morbid myeloproliferative disorders in the US population. Age-adjusted mortality rates (AAMRs) and 95% confidence intervals (CIs) were computed per 1 million population by standardizing crude mortality rates to the 2000 US census population. To assess annual national mortality trends, we employed the Joinpoint regression model, calculating the annual per cent change in AAMR and corresponding 95% CIs. A total of 15 269 deaths related to CVD occurred in patients with co-morbid MPNs from 1999 to 2020. Overall, there was a decreasing trend in CVD-related AAMRs throughout these years. Males contributed to 51% of total deaths, and their AAMR was persistently higher than women throughout the study. Non-Hispanic (NH) Whites had the highest overall AAMR, followed by NH Blacks, NH American Indians or Alaska Natives, Hispanics or Latinos, and NH Asian or Pacific Islanders. Conclusion Our findings indicate a significant decline with notable gender, racial/ethnic, and regional differences in CVD-related mortality among patients with MPN over the past two decades. We emphasize the importance of a collaborative approach between oncologists and cardiologists in managing these patients, highlighting the potential benefits of integrating cardio-oncology services to enhance patient outcomes.
NCCN Guidelines® Insights: Survivorship, Version 2.2024
Sanft, Tara , Goldman, Mindy, Ansbaugh, Shannon, Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Schapira, Lidia , Ah, Diane Von , Wake, Robert, Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Ballinger, Tarah Jean , Demark‐Wahnefried, Wendy , Friedman, Debra L. , Lee, Kimberley T. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Schwartz, Anna L. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 648-658

10.6004/jnccn.2024.0062 | PMID 39689426 Get It

The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
Which Osteochondritis Dissecans Lesions Will Heal Nonoperatively? An Application of Machine Learning to the ROCK Prospective Cohort
Johnstone, T, Espiritu, Joseph , Tompkins, Marc , Milewski, Matthew D. , Nissen, Carl W. , Shea, Kevin G. , Group:, the ROCK, Egger, Anthony C. , Anderson, Christian N. , Pace, James Lee, Polousky, John D. , Ellemann, Jutta, Meenen, N. M., Ellis, Henry B. , Carey, James, Nissen, Carl , Espiritu, Joseph, Group:, the ROCK, Nelson, Bradley J. , Pace, James Lee, Edmonds, Eric W. , Fabricant, Peter D , Krych, Aaron J. , Myer, Gregory D. , Kocher, Mininder Singh , Carey, James

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 16, 2024 | Volume: 12 | Issue: 12 | Pages: No page available

10.1177/23259671241297145 | PMID 39697601 Get It

Background: There are limited evidence-based guidelines to predict which osteochondritis dissecans (OCD) lesions will heal with nonoperative treatment. Purpose: To train a set of classification algorithms to predict nonoperative OCD healing while identifying new clinically meaningful predictors. Study Design: Case-control study; Level of evidence, 3. Methods: Patients with OCD of the knee with open physes undergoing nonoperative management were prospectively queried from the Research on OCD of the Knee (ROCK) cohort ( https://kneeocd.org ) in April 2022. Patients were included if they met the study criteria for nonoperative treatment success or failure. Nonoperative treatment success was defined as complete healing on magnetic resonance imaging (MRI) and total return to sports participation. Failure was defined as the crossover from nonoperative management to surgery at any point at or beyond the 3-month follow-up. If a patient did not meet one of these criteria, they were not included. Normalized lesion size, lesion location, patient characteristics, and symptoms were used as clinically relevant predictors. Results: A total of 64 patients were included, of whom 24 (37.5%) patients successfully healed with nonoperative management. Multivariate logistic regression revealed that a 1% increase in normalized lesion width was associated with an increase in the likelihood of nonoperative failure (odds ratio [OR], 1.41 [95% CI, 1.17-1.81]; P < .01). By contrast, lesions in the posterior sagittal zone (OR, 0.08 [95% CI, 0.009-0.43]; P < .01) or the medial-most coronal zone (for lesions of the medial femoral) and lateral-most coronal zone (for lesions of the lateral femoral condyle) on MRI (OR, 0.05 [95% CI, 0.004-0.44]; P < .01) were associated with a decrease in the likelihood of nonoperative treatment failure. Support vector machines had a cross-validated area under the receiver operating characteristic curve of 0.89 and a classification accuracy of 83.3%. Conclusion: Lesion location in the posterior aspect of the condyle on sagittal MRI and lesion location in the medial-most or lateral-most locations on coronal MRI were identified as statistically significant predictors of increased nonoperative treatment success on multivariate analysis. Machine learning models can predict which OCD lesions will heal with nonoperative management with superior accuracy compared with previously published models.
National Trends and Benchmarks for Operative Time and Hospital Length of Stay in Parotidectomies
Calcano, Gabriela A. , Rourk, Katelyn S. , Glasgow, Amy E. , Henson, Jeanne, Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Glasgow, Amy, Henson, Jammie, Yin, Linda X , Van Abel, Kathryn M , Habermann, Elizabeth B. , Henson, Jammie, Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 15, 2024 | Volume: 172 | Issue: 3 | Pages: 913-921

10.1002/ohn.1084 | PMID 39675031 Get It

AbstractObjectiveThe extent of parotidectomy for benign tumors has de‐escalated in the United States. We aim to define modern benchmarks for operative time and hospital length of stay (LOS) in parotidectomy and identify risk factors that may prolong these benchmarks.Study DesignThis is a retrospective cross‐sectional study of all adults who underwent parotidectomy for a primary parotid neoplasm between January 2011 and December 2021 using the American College of Surgeons National Surgical Quality Improvement Program database.MethodsThe extent of parotidectomy was defined using Current Procedural Terminology codes. Prolonged operative time and LOS were defined as above the 75th percentile (longer than 194 minutes and more than 1 day, respectively). Multivariable logistic regression was used to identify patient and surgical risk factors that predict prolonged operative time or LOS.ResultsBenign parotidectomies are mostly performed as outpatient procedures in the United States (average LOS <1 day). Prolonged operative time was independently associated with malignant tumors versus benign tumors (adjusted odds ratio [aOR]: 2.7, 95% confidence interval [CI]: 2.4‐3.0), total parotidectomy with facial nerve sacrifice versus lesser extent of parotidectomy (aOR: 2.3, 95% CI: 1.7‐3.0), and simultaneous reconstructive procedures versus none (P < .001 for all). These features were similarly independently associated with prolonged LOS (P < .001 for all). Complication rates were universally low.ConclusionThe majority of superficial parotidectomies in this country are performed as outpatient procedures requiring <3 hours of operative time, with low complication rates. Malignant tumors, greater extent of parotidectomy, and simultaneous procedures were independently associated with prolonged operative time and LOS. These national benchmarks can inform operating room and hospital bed resource assignments.
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Jack, Clifford R. , Graf, Ana, Doty, Erin , Moebius, Hans J. , Montenigro, Philip H. , Siemers, Eric , Sink, Kaycee M. , Shaw, Leslie M. , Hansen, Charlotte T., Wildsmith, Kristin R., Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Jack, Clifford R , Burnham, Samantha C. , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | December 14, 2024 | Volume: 10 | Issue: 4 | Pages: No page available

10.1002/trc2.70013 | PMID 39748835 Get It

Abstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the Revised Criteria for Diagnosis and Staging of AD: AA Workgroup , and gather industry perspectives and feedback on these revised criteria before its publication. The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care. Improving the availability and accuracy of biomarkers, especially blood‐based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.
Olfactory function is reduced in a subset of former elite American football players with traumatic encephalopathy syndrome
Braunecker, Ben J, Groh, Jenna R., Adler, Charles H. , Alosco, Michael L. , Tripodis, Yorghos , Balcer, Laura J. , Bernick, Charles , Banks, Sarah J. , Wethe, Jennifer V. , Palmisano, Joseph , Martin, Brett, Hartlage, Kaitlin , Geda, Yonas E. , Cummings, Jeffery L., Shenton, Martha E., Reiman, Eric M. , Braunecker, Ben J. , Tripodis, Yorghos , Adler, C H , Geda, Yonas E , Wethe, Jennifer V , Braunecker, Ben J. , Groh, Jenna R. , Dodick, David W. , Barr, William , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Shenton, M.E., Stern, Robert A.

Mayo Clinic

Chemical Senses | December 11, 2024 | Volume: 49 | Issue: No issue available | Pages: No page available

10.1093/chemse/bjae043 | PMID 39657828 Get It

Abstract Former American football players are at risk for developing traumatic encephalopathy syndrome (TES), the clinical disorder associated with neuropathologically diagnosed chronic traumatic encephalopathy (CTE). The objective of this study was to determine whether hyposmia is present in traumatic encephalopathy syndrome. The study included 119 former professional American football players, 60 former college football players, and 58 same-age asymptomatic unexposed men from the DIAGNOSE CTE Research Project. All subjects included in the analysis had completed the Brief Smell Identification Test (B-SIT). Traumatic encephalopathy syndrome and the level of CTE certainty were diagnosed using the 2021 NINDS consensus diagnostic criteria. TES is categorized antemortem by provisional levels of increasing CTE certainty: Suggestive, Possible, and Probable. Former players who had traumatic encephalopathy syndrome and Probable CTE had lower B-SIT scores than those with TES and Suggestive CTE. Hyposmia was more likely in the former players with TES who were either CTE Possible or Probable than in those who did not have TES or had TES but were less likely to have CTE, or CTE Suggestive. There was no difference in B-SIT scores between all former players versus unexposed men nor overall between the football players with and without TES. We conclude that lower B-SIT scores may be a clinical biomarker for underlying CTE in former American football players.
(236) HOW OFTEN DO PATIENTS ELECT SURGERY FOLLOWING XIAFLEX TREATMENT FOR PEYRONIE’S DISEASE?
Qosja, Neda, Haehn, Daniela A. , Regele, Eric J. , Hampton, S, Qualkenbush, Eric , Baird, Bryce , Aldridge, Harold E., Schommer, Jon C. , Qualkenbush, Eric , Aldridge, H, Ball, C, Broderick, Gregory A.

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.230 Get It

Abstract Introduction Peyronie’s disease (PD) is a fibrosing condition of the tunica albuginea characterized by a palpable plaque with varying impacts on the patient’s erection: curvature, shortening, indentations, hinging, and concentric narrowing. Stepwise intralesional injection of collagenase clostridium histolyticum (Xiaflex) is the only FDA approved medical treatment for PD. We retrospectively reviewed Xiaflex treated patients for satisfaction with therapy or pursuit of subsequent surgery. Objective To assess satisfaction of Xiaflex treatment without subsequent surgical intervention. Methods This is a retrospective review of patients presenting with PD to a single center and managed by a single provider with six-month follow-up after treatment. Patient presentations were recorded in an Institutional Review Board approved database. Data storage and analytics were conducted using REDCap. Results The cohort for this study was 81 men treated with intralesional Xiaflex. 71.6% of patients (58/81) were satisfied with Xiaflex outcomes and sought no further therapy. 27.2% of patients (22/81) were not satisfied with their outcomes and 12 (14.8%) elected subsequent surgical interventions: 6 penile plications, 2 incision and graftings and 4 inflatable penile prostheses. 63.3% of patients had full (8) Xiaflex treatment. Among the 50 who had full Xiaflex treatment, 12% had surgery after Xiaflex. Among the patients who had partial Xiaflex treatment 20.7% had surgery following Xiaflex. The degrees of curvature in patients receiving Xiaflex was: &lt; 60 (n = 42), ≥ 60 (34) and hourglass deformity (n = 4). Among the 12 patients who had surgery following Xiaflex, 6 men received 8 Xiaflex treatments, and 1 patient each received 2, 4, 5, 6, and 7 Xiaflex treatments. Conclusions If successful medical management of Peyronie’s disease is defined by men who do not seek subsequent surgical intervention following therapy, Xiaflex was highly successful. In our series of 81 patients, only 14.8% sought surgical interventions following intralesional collagenase histolyticum. Disclosure No.
Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire
Wong, Sui H. , Abuzaitoun, Rebhi , Cornblath, Wayne T. , Eggenberger, Eric , Khanna, Sangeeta , Deveney, Tatiana , Ehrlich, Joshua R. , Andrews, Chris , Barnett, Carolina , Lott, Lindsey B. De , Wong, Sui Hsien , Eggenberger, Eric R , Andrews, Chris A , Barnett-Tapia, Carolina , De Lott, Lindsey B , Khanna, Sangeeta

Mayo Clinic

Neurology | December 10, 2024 | Volume: 104 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000210150 | PMID 39657098 Get It